Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Lab-on-a-Chip, Microfluidics & Microarrays World Congress 2016

Nancy Allbritton's Biography



Nancy Allbritton, Professor and Chair, University of North Carolina

Dr. Allbritton obtained her Ph.D. in Medical Physics/Medical Engineering from the Massachusetts Institute of Technology, and her M.D. from the Johns Hopkins University. Currently, she is the Kenan Professor and Chair of the Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill (UNC) and the North Carolina State University. She has received multiple awards and is a Fellow in the American Institute for Medical & Biological Engineering and a member of the National Academy of Inventors. Dr. Allbritton's research studies are directed at the development of new technologies by bringing to bear methods from engineering, chemistry, physics and biology to address biomedical problems. Dr. Allbritton is the scientific founder of four companies and has 12 issued patents with over multiple pending patents.

Nancy Allbritton Image

Microraft Array Platform for the Selection of Lymphocytes Based on Target-Cell Killing

Tuesday, 27 September 2016 at 13:30

Add to Calendar ▼2016-09-28 14:00:002016-09-28 15:00:00Europe/LondonMicroraft Array Platform for the Selection of Lymphocytes Based on Target-Cell KillingLab-on-a-Chip, Microfluidics and Microarrays World Congress 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com

Adoptive cellular therapy (ACT) is an emerging therapeutic in which cytotoxic T lymphocytes (CTLs) that recognize tumor cell epitopes are introduced into patients providing immunity against the cancer cells. For ACT to succeed, CTLs with high tumor-killing efficiency must be identified, isolated, and characterized. Current technologies do not enable simultaneous assay of cell behavior or killing followed by recovery of the most efficient killer cells. A microraft array technology that measures the ability of individual T cells to lyse a population of target cells followed by sorting of living cells into a multi-well plate for expansion and characterization was developed.  The microraft array platform was combined with image processing and analysis algorithms to track and monitor killing assays over many hours. Automated cell collection was incorporated into the platform for facile cell collection from the array. As a proof of principle, human T cells directed against an influenza antigen were co-cultured with antigen presenting target cells on the microraft arrays. Target cell killing was measured by tracking the appearance of dead cells on each microraft over time. Microrafts with a single CTL demonstrating the greatest rate of target cell death were identified, cloned, and influenza-antigen reactivity confirmed. The platform is readily modified to measure the antigen-specific activity of individual cells within a bulk CTL culture or the cell heterogeneity within a population of gene-engineered T cells.


Add to Calendar ▼2016-09-26 00:00:002016-09-28 00:00:00Europe/LondonLab-on-a-Chip, Microfluidics and Microarrays World Congress 2016Lab-on-a-Chip, Microfluidics and Microarrays World Congress 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com